Statements (24)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
|
| gptkbp:approvalYear |
1984
|
| gptkbp:approvedBy |
gptkb:FDA
|
| gptkbp:ATCCode |
gptkb:A02BA02
|
| gptkbp:brand |
gptkb:ranitidine
|
| gptkbp:chemicalClass |
histamine H2-receptor antagonist
|
| gptkbp:discoveredIn |
1977
|
| https://www.w3.org/2000/01/rdf-schema#label |
Azantac
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:manufacturer |
GlaxoSmithKline
|
| gptkbp:routeOfAdministration |
oral
intravenous |
| gptkbp:sideEffect |
diarrhea
constipation dizziness headache |
| gptkbp:usedFor |
treatment of peptic ulcer disease
treatment of heartburn treatment of gastroesophageal reflux disease |
| gptkbp:withdrawn |
gptkb:United_States
2020 NDMA contamination concerns |
| gptkbp:bfsParent |
gptkb:CHEMBL1487
|
| gptkbp:bfsLayer |
7
|